Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 12, 2019 4:05 PM ESTNew Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last Visit Implemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020 Received CE Mark Approval for Renevia®; Working to Identify European Commercial Partner Conducted Sales of 6.25 Million Shares of OncoCyte Corporation for $10.7 Million in Net Proceeds Strengthened Extensive IP Portfolio with the Issuance of 3 New U.S. Patents Awarded Additional NIH Grant for Innovative Vision Restoration Program
CARLSBAD,... More
